Skip to main content
Erschienen in: Urolithiasis 5/2021

08.02.2021 | Original Paper

Is medical treatment necessary for infants with small urinary stones?

verfasst von: Funda Bastug, Binnaz Celık

Erschienen in: Urolithiasis | Ausgabe 5/2021

Einloggen, um Zugang zu erhalten

Abstract

Urinary stone disease is a common condition. We investigated the usefulness of medical treatment for infants with urinary stones 5 mm or smaller. The study included 197 infants (86 girls and 111 boys) with urolithiasis ≤ 5 mm who were referred to our Department of Nephrology between 2014 and 2016. Infants with metabolic or anatomical risk factors requiring medical treatment were excluded from the study. We retrospectively reviewed urine and serum metabolic profiles and compared stone resolution rates in patients who did and did not receive treatment. The mean age at diagnosis was 5.2 months (range, 14 days to 12 months). The most common complaint was restlessness (n = 92, 46.7%), and 49 infants (24.9%) were asymptomatic. Multiple stones were detected in 166 infants (84.3%). Hypomagnesuria, hypocitraturia, and hypercalciuria were present in 25.3, 19.7, and 18.7% of patients, respectively. Stones < 3 mm (microlithiasis) were detected in 97 infants (49.2%), and 100 (50.8%) patients had 3–5 mm stones. In total, 130 infants (66.5%) received regular treatment and 67 (33.5%) were not treated. Stone resolution was significantly higher in the group receiving K-citrate treatment at the 6th month follow-up, while there were no significantly difference between the two groups at the 12th month control. No previous studies have investigated treatment outcomes in infants with 3–5 mm urinary stones. According to our results, K-citrate treatment may accelerate the resolution of the stone in infants with stones smaller than 5 mm.
Literatur
1.
Zurück zum Zitat Serdaroğlu E, Aydoğan M, Özdemir K, Bak M (2017) Incidence and causes of urolithiasis in children between 0–2 years. Minerva Urol Nefrol 69(2):181–188PubMed Serdaroğlu E, Aydoğan M, Özdemir K, Bak M (2017) Incidence and causes of urolithiasis in children between 0–2 years. Minerva Urol Nefrol 69(2):181–188PubMed
2.
Zurück zum Zitat Baştuğ F, Gündüz Z, Tülpar S, Poyrazoğlu H, Düşünsel R (2013) Urolithiasis in infants: evaluation of risk factors. World J Urol 31:1117–1122CrossRef Baştuğ F, Gündüz Z, Tülpar S, Poyrazoğlu H, Düşünsel R (2013) Urolithiasis in infants: evaluation of risk factors. World J Urol 31:1117–1122CrossRef
3.
Zurück zum Zitat Alpay H, Gokce I, Ozen A, Bıyıklı N (2013) Urinary stone disease in the first year of life: is it dangerous? Pediatr Surg Int 29:311–316CrossRef Alpay H, Gokce I, Ozen A, Bıyıklı N (2013) Urinary stone disease in the first year of life: is it dangerous? Pediatr Surg Int 29:311–316CrossRef
4.
Zurück zum Zitat Penido MG, Tavares MS (2015) Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies. World J Nephrol 4(4):444–454CrossRef Penido MG, Tavares MS (2015) Pediatric primary urolithiasis: Symptoms, medical management and prevention strategies. World J Nephrol 4(4):444–454CrossRef
5.
Zurück zum Zitat Alon US (2009) Medical treatment of pediatric urolithiasis. Pediatr Nephrol 24:2129–2135CrossRef Alon US (2009) Medical treatment of pediatric urolithiasis. Pediatr Nephrol 24:2129–2135CrossRef
6.
Zurück zum Zitat Baştuğ F, Düşünsel R (2012) Pediatric urolithiasis: causative factors, diagnosis and medical management. Nat Rev Urol 9:138–146CrossRef Baştuğ F, Düşünsel R (2012) Pediatric urolithiasis: causative factors, diagnosis and medical management. Nat Rev Urol 9:138–146CrossRef
7.
Zurück zum Zitat Jobs K, Rakowska M, Paturej A (2018) Urolithiasis in the pediatric population - current opinion on epidemiology, patophysiology, diagnostic evaluation and treatment. Dev Period Med 22(2):201–208PubMed Jobs K, Rakowska M, Paturej A (2018) Urolithiasis in the pediatric population - current opinion on epidemiology, patophysiology, diagnostic evaluation and treatment. Dev Period Med 22(2):201–208PubMed
8.
Zurück zum Zitat Andriolia V, Highmoreb K, Leonardo MP, Guerra LA, Tangc K, Vethamuthud J, Meyersa V, Sullivana KJ, August MAK (2017) Infant nephrolithiasis and nephrocalcinosis: natural history and predictors of surgical intervention. J Pediatr Urol 13(4):355.e1-355.e6CrossRef Andriolia V, Highmoreb K, Leonardo MP, Guerra LA, Tangc K, Vethamuthud J, Meyersa V, Sullivana KJ, August MAK (2017) Infant nephrolithiasis and nephrocalcinosis: natural history and predictors of surgical intervention. J Pediatr Urol 13(4):355.e1-355.e6CrossRef
9.
Zurück zum Zitat Güven AG, Koyun M, Baysal YE, Akman S, Alimoglu E, Akbas H, Kabaalioglu A (2010) Urolithiasis in the first year of life. Pediatr Nephrol 25:129–134CrossRef Güven AG, Koyun M, Baysal YE, Akman S, Alimoglu E, Akbas H, Kabaalioglu A (2010) Urolithiasis in the first year of life. Pediatr Nephrol 25:129–134CrossRef
10.
Zurück zum Zitat Alemzadeh-Ansari MH, Valavi E, Ahmadzadeh A (2014) Predisposing factors for infantile urinary calculus in south-west of Iran. Iran J Kidney Dis 8(1):53–57PubMed Alemzadeh-Ansari MH, Valavi E, Ahmadzadeh A (2014) Predisposing factors for infantile urinary calculus in south-west of Iran. Iran J Kidney Dis 8(1):53–57PubMed
11.
Zurück zum Zitat Kunj RS, WhitePerez-Orozco TJAF, Natalie D et al (2018) Evaluating natural history and follow up strategies for non-obstructive urolithiasis in pediatric population. Front Pediatr 6:353CrossRef Kunj RS, WhitePerez-Orozco TJAF, Natalie D et al (2018) Evaluating natural history and follow up strategies for non-obstructive urolithiasis in pediatric population. Front Pediatr 6:353CrossRef
12.
Zurück zum Zitat Goldsmith ZG, Lipkin ME (2012) When (and how) to surgically treat asymptomatic renal stones. Nat Rev Urol 9:315–320CrossRef Goldsmith ZG, Lipkin ME (2012) When (and how) to surgically treat asymptomatic renal stones. Nat Rev Urol 9:315–320CrossRef
13.
Zurück zum Zitat Ordon M, Andonian S, Blew B, Schuler T, Chew B, Pace KT (2015) CUA guideline: Management of ureteral calculi. Can Urol Assoc J 9(11–12):E837–E851CrossRef Ordon M, Andonian S, Blew B, Schuler T, Chew B, Pace KT (2015) CUA guideline: Management of ureteral calculi. Can Urol Assoc J 9(11–12):E837–E851CrossRef
14.
Zurück zum Zitat Milliner DS (2009) Urolithiasis. In: Avner ED, Harman WE, Niaudet P, Yoshikawa N (eds) Pediatric nephrology, 6th edn. Springer, Berlin, pp 1405–1424CrossRef Milliner DS (2009) Urolithiasis. In: Avner ED, Harman WE, Niaudet P, Yoshikawa N (eds) Pediatric nephrology, 6th edn. Springer, Berlin, pp 1405–1424CrossRef
15.
Zurück zum Zitat Telli O, Hamidi N, Bagci U, Demirbas A, Hascicek AM, Soygur T, Burgu B (2017) What happens to asymptomatic lower pole kidney Stones smaller than 10 mm in children during watcful waiting? Pediatr Nephrol 32(5):853–857CrossRef Telli O, Hamidi N, Bagci U, Demirbas A, Hascicek AM, Soygur T, Burgu B (2017) What happens to asymptomatic lower pole kidney Stones smaller than 10 mm in children during watcful waiting? Pediatr Nephrol 32(5):853–857CrossRef
16.
Zurück zum Zitat Zafar MN, Ayub S, Tanwri H, Naqvi SAA, Rizvi SAH (2018) Composition of urinary calculi in infants: a report from an endemic country. Urolithiasis 46(5):445–452CrossRef Zafar MN, Ayub S, Tanwri H, Naqvi SAA, Rizvi SAH (2018) Composition of urinary calculi in infants: a report from an endemic country. Urolithiasis 46(5):445–452CrossRef
17.
Zurück zum Zitat Tekin A, Tekgul S, Atsu N, Sahin A, Ozen H, Bakkaloglu M (2000) A study of the etiology of idiopathic calcium urolithiasis in children: hypocitraturia is the most important factor. J Urol 164(1):162–165CrossRef Tekin A, Tekgul S, Atsu N, Sahin A, Ozen H, Bakkaloglu M (2000) A study of the etiology of idiopathic calcium urolithiasis in children: hypocitraturia is the most important factor. J Urol 164(1):162–165CrossRef
18.
Zurück zum Zitat Ergon EY, Akil IO, Taneli F, Oran A, Ozyurt BC (2018) Etiologic risk factors and vitamin D receptor gene polymorphisms in under one-year old infants with urolithiasis. Urolithiasis 46(4):349–356CrossRef Ergon EY, Akil IO, Taneli F, Oran A, Ozyurt BC (2018) Etiologic risk factors and vitamin D receptor gene polymorphisms in under one-year old infants with urolithiasis. Urolithiasis 46(4):349–356CrossRef
19.
Zurück zum Zitat Elmacı AM, Ece A, Akın F (2014) Pediatric urolithiasis: metabolic risk factors and follow-up results in a Turkish region with endemic stone Disease. Urolithiasis 42:421–426CrossRef Elmacı AM, Ece A, Akın F (2014) Pediatric urolithiasis: metabolic risk factors and follow-up results in a Turkish region with endemic stone Disease. Urolithiasis 42:421–426CrossRef
Metadaten
Titel
Is medical treatment necessary for infants with small urinary stones?
verfasst von
Funda Bastug
Binnaz Celık
Publikationsdatum
08.02.2021
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 5/2021
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-021-01248-4

Weitere Artikel der Ausgabe 5/2021

Urolithiasis 5/2021 Zur Ausgabe

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Harninkontinenz: Netz-Op. erfordert über lange Zeit intensive Nachsorge

30.04.2024 Harninkontinenz Nachrichten

Frauen mit Belastungsinkontinenz oder Organprolaps sind nach einer Netz-Operation keineswegs beschwerdefrei. Vielmehr scheint die Krankheitslast weiterhin hoch zu sein, sogar höher als von harninkontinenten Frauen, die sich nicht haben operieren lassen.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.